Search filters

Filters
Clear All

Phase

  • 10
  • 15
  • 17
  • 11
  • 19
  • 76
  • 36
  • 3
  • 2
  • 71
  • 74
  • 2

Found 76 Chemotherapy trials

A listing of Chemotherapy medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

99 years or below
All genders
Phase II and III: To compare time to DFS event (recurrence, second primary colorectal can cer or death) in ctDNA (+ve) cohort following resection of colon cancer treated with 5-FU (orcapecitabine) and oxaliplatin x 6 months or 5-FU, oxaliplatin and irinotecan x 6 months.
99 years or below
All genders
The main purpose of this research study is to find out whether Selective Internal Radiation Therapy (SIRT) preceding a standard chemotherapy treatment can improve survival in patients with cholangiocarcinoma in the liver, compared to chemotherapy alone.
18 years - 99 years
All genders
Interventional
The purpose of this research study is to compare the performance of the investigational (experimental) tricuspid valve repair system plus optimal drug therapy with optimal drug therapy alone. Participants will be randomly assigned to treatment with either the TriClip device (device group) or No TriClip device (control group). Participants will …
 REVOLUTION: Trial to Evaluate Immunotherapy Combinations with Chemotherapy for the Treatment of Patients with Previously Untreated Metastatic Pancreatic Adenocarcinoma
18 years - 99 years
All genders
Phase 1
This is a phase 1 study that enrolls subjects with metastatic pancreatic adenocarcinoma. The purpose of this study is to learn about the safety and efficacy of a combination of 4 study drugs: ipilimumab (ipi), nab-paclitaxel (nP), gemcitabine (gem), and hydroxychloroquine (HCQ). This is an open-label, non-randomized, exploratory platform trial …
 Open Label Study Investigating the Efficacy and Safety of Roxadustat for Treatment of Anemia in Patients Receiving Chemotherapy Treatment for Non-Myeloid Malignancies
18 years - 99 years
All genders
Phase 2
The main purpose of this study is to find out if the experimental drug roxadustat (also known as FG-4592) is safe and effective for potentially treating anemia in people receiving chemotherapy treatments for cancer. 800x600 Normal 0 false false false EN-US X-NONE X-NONE MicrosoftInternetExplorer4 In order to take part in …
 Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)  A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
99 years or below
All genders
Phase 3
The purpose of this study is to find if adding the study drug, nivolumab (also known as OPVIDO), will limit lung cancer from growing back in patients with early stage non-small cell lung cancer. Nivolumab is a drug that may turn on the body's immune system to attack any cancer …
 Study to Assess the Efficacy and Safety of BST-236 in Adults Unfit for Intensive Chemotherapy with Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndromes
18 years - 99 years
All genders
Phase 2
Interventional
An open label multi center study to assess the safety and efficacy of BST-236 as single agent in adult patients unfit for standard therapy with Acute Myeloid Leukemia (AML) or higher-risk (HR) Myelodysplastic Syndromes (MDS) who fail to respond or relapsed following first line therapy.
 UPCC 06717 / AMC 101: A Pilot Study of Ibrutinib and R-da-EPOCH for Front Line Treatment of AIDS-Related Lymphomas
18 years - 64 years
All genders
Phase 1
Non-Hodgkin lymphoma  is a potentially curable condition with standard cancer treatment drugs (chemotherapy) and steroids. Standard lymphoma treatment includes chemotherapy, or cancer-fighting drugs, called etoposide, vincristine, cyclophosphamide, prednisone and doxorubicin (called EPOCH).  
18 years - 99 years
All genders
Phase 2
The purpose of this study is to compare the effectiveness of gilteritinib to midostaurin in patients receiving standard combination chemotherapy for FLT3 AML. Eligible untreated patients with FLT3 acute myeloid leukemia (AML) between the ages of 18 and 65 will be randomized to receive gilteritinib or midostaurin during induction and …